Glenview State Bank Trust DEPT. lessened its stake in Medtronic PLC (NYSE:MDT) by 17.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,696 shares of the medical technology company’s stock after selling 1,000 shares during the period. Glenview State Bank Trust DEPT.’s holdings in Medtronic were worth $366,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MDT. Parkside Financial Bank & Trust grew its position in shares of Medtronic by 22.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after acquiring an additional 210 shares during the period. BDO Wealth Advisors LLC bought a new position in Medtronic in the 2nd quarter worth $103,000. Motco boosted its holdings in Medtronic by 8.7% in the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock worth $110,000 after buying an additional 99 shares during the period. Quadrant Capital Group LLC boosted its holdings in Medtronic by 21.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock worth $114,000 after buying an additional 290 shares during the period. Finally, Israel Discount Bank of New York bought a new position in Medtronic in the 1st quarter worth $117,000. 81.85% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Bryan C. Hanson sold 16,000 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $78.03, for a total transaction of $1,248,480.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the sale, the chief executive officer now owns 668,503 shares in the company, valued at approximately $54,569,899.89. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,407 shares of company stock worth $13,974,223. Insiders own 0.31% of the company’s stock.

Several research analysts recently weighed in on the stock. Cowen set a $95.00 target price on shares of Medtronic and gave the stock a “buy” rating in a report on Tuesday, August 22nd. Oppenheimer reiterated a “buy” rating and issued a $92.00 price target on shares of Medtronic in a research note on Tuesday, August 22nd. Royal Bank Of Canada reiterated a “buy” rating and issued a $90.00 price target on shares of Medtronic in a research note on Monday, August 21st. BidaskClub upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Stifel Nicolaus upped their target price on shares of Medtronic from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the company. Medtronic currently has a consensus rating of “Hold” and a consensus target price of $88.02.

Medtronic PLC (NYSE:MDT) traded down $0.93 during midday trading on Friday, hitting $80.57. 5,497,500 shares of the stock were exchanged, compared to its average volume of 4,962,533. The company has a current ratio of 2.40, a quick ratio of 2.05 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1 year low of $69.35 and a 1 year high of $89.72. The company has a market capitalization of $110,310.08, a P/E ratio of 17.57, a PEG ratio of 2.25 and a beta of 1.00.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The firm had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $7.05 billion. During the same period last year, the firm earned $1.12 earnings per share. The company’s quarterly revenue was down 4.0% on a year-over-year basis. equities research analysts expect that Medtronic PLC will post 4.77 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Medtronic PLC (MDT) Position Trimmed by Glenview State Bank Trust DEPT.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/08/medtronic-plc-mdt-position-trimmed-by-glenview-state-bank-trust-dept.html.

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.